Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Director/PDMR Shareholding

16 Sep 2021 11:17

RNS Number : 0206M
InnovaDerma PLC
16 September 2021
Β 

InnovaDerma PLC

("InnovaDerma" or the "Company")

Director/PDMR shareholding

InnovaDerma (LSE: IDP), a leading digitally focused UKΒ beauty brand developer, announces that it was notified on 14 September 2021, Mark Ward, Non-executive Director has purchased 223,133Β Ordinary Shares of €0.10 each in the Company at a price of 40.5 pence per Ordinary Share.

Following the purchase, Mark Ward now holds a total ofΒ 4,672,277 Ordinary Shares representing approximately 17.07% of the issued share capital of the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiriesΒ Β 

InnovaDermaΒ Β 

Blake HughesΒ 

β€―

β€―

c/o TB CardewΒ 

β€―

finnCapβ€―LtdΒ Β 

Geoff Nash/Kate BannatyneΒ 

Alice Lane - Corporate BrokingΒ 

β€―

+44 (0)207 220 0500Β 

www.finncap.comΒ 

TB CardewΒ Β 

Shan Shan Willenbrock/Β 

Olivia RosserΒ 

β€―

+ 44 (0)7775 848537Β 

+ 44 (0)20 7930 0777Β 

innovaDerma@tbcardew.com

β€―

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Β 

1.Β 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mark Ward

2.Β 

Reason for the Notification

Β 

a)

Position/status

Non-executive Director

b)

Initial notification/Amendment

Initial notification

3.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Name

InnovaDerma PLC

Β 

b)

LEI

213800WRAP6W8VDL6B38

Β 

4.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Description of the Financial instrument, type of instrument

€0.10 each ("Ordinary Shares")

Identification code

IDP GB00BT9PTW34

Β 

b)

Nature of the transaction

Purchase of Ordinary Shares

Β 

c)

Price(s) and volume(s)

Volume - 223,133Β Ordinary Shares

Price - 40.5 pence per Ordinary Share

Β 

d)

Aggregated information:

Aggregated volume

Price

Β 

See 4c) above

Β 

e)

Date of the transaction

14 September 2021

Β 

f)

Place of the transaction

London Stock Exchange, Main Market

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHUNARRAVUKAAR
Date   Source Headline
31st May 20221:57 pmRNSScheme of Arrangement Becomes Effective
27th May 20224:01 pmRNSCourt Sanction of Scheme and Suspension
27th May 202210:21 amRNSForm 8.5 (EPT/RI)
25th May 202211:10 amRNSForm 8.5 (EPT/RI)
24th May 202211:48 amRNSForm 8.5 (EPT/RI)
23rd May 202211:49 amRNSForm 8.5 (EPT/RI)
19th May 20223:29 pmRNSResults of Court Meeting and General Meeting
19th May 20229:47 amRNSForm 8.5 (EPT/RI)
16th May 202210:35 amRNSForm 8.5 (EPT/RI)
12th May 202210:13 amRNSForm 8.5 (EPT/RI)
10th May 20229:05 amRNSForm 8.5 (EPT/RI)
9th May 202211:45 amRNSForm 8.5 (EPT/RI)
5th May 202210:00 amRNSScheme Timetable
5th May 20229:04 amRNSForm 8.5 (EPT/RI)
4th May 20229:51 amRNSForm 8.5 (EPT/RI)
3rd May 202210:48 amRNSForm 8.3 - InnovaDerma plc
3rd May 202210:29 amRNSForm 8.5 (EPT/RI)
27th Apr 202211:06 amRNSForm 8.5 (EPT/RI)
25th Apr 20221:31 pmRNSForm 8.3 - InnovaDerma PLC
25th Apr 202212:35 pmRNSPublication of Circular/Notice of General Meeting
25th Apr 202212:30 pmRNSPosting of Scheme Document & IMC Presentation
21st Apr 20221:00 pmRNSForm 8.3 - InnovaDerma PLC
20th Apr 202212:07 pmRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
14th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20226:06 pmRNSForm 8.3 - Innovaderma PLC
13th Apr 20224:30 pmRNSForm 8 (OPD) - InnovaDerma plc
13th Apr 20224:03 pmRNSForm 8.3 - Offeree - InnovaDerma PLC
13th Apr 202211:40 amRNSForm 8.3 - InnovaDerma PLC
13th Apr 20228:47 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20227:00 amRNSForm 8.3 - InnovaDerma PLC
12th Apr 202212:31 pmRNSForm 8.3 - InnovaDerma plc
11th Apr 20226:14 pmRNSForm 8 (OPD) InnovaDerma PLC
8th Apr 20223:00 pmRNSForm 8 (OPD) - InnovaDerma plc
8th Apr 202210:33 amRNSForm 8.5 (EPT/RI)
7th Apr 20229:51 amRNSForm 8.5 (EPT/RI)
6th Apr 202211:03 amRNSForm 8.5 (EPT/RI)
5th Apr 20221:01 pmRNSForm 8.3 - Innovaderma PLC
5th Apr 202211:25 amRNSForm 8.3 - InnovaDerma PLC
4th Apr 202211:16 amRNSForm 8.5 (EPT/RI)
1st Apr 20225:32 pmRNSForm 8.3 - Innovaderma PLC
1st Apr 202211:56 amRNSForm 8.5 (EPT/RI)
1st Apr 202211:00 amRNSForm 8 (DD) - InnovaDerma PLC
31st Mar 20224:44 pmRNSForm 8.3 - Innovaderma Plc
31st Mar 20224:41 pmRNSSecond Price Monitoring Extn
31st Mar 20224:36 pmRNSPrice Monitoring Extension
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 20227:01 amRNSRecommended Merger with InnovaDerma Plc
31st Mar 20227:00 amRNSInterim Results
27th Jan 20224:10 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.